Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Creation of Working Cell Bank (WCB) – V 2.0

Posted on By


Biosimilars: SOP for Creation of Working Cell Bank (WCB) – V 2.0


Standard Operating Procedure for Creation of Working Cell Bank (WCB) for Biosimilars

Department Biosimilars
SOP No. SOP/BS/025/2025
Supersedes SOP/BS/025/2022
Page No. Page 1 of 13
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for the generation, labeling, freezing, testing, and storage of the Working Cell Bank (WCB) derived from a qualified Master Cell Bank (MCB) for biosimilar production use.

2. Scope

This SOP applies to Cell Line Development, Quality Control, and Quality Assurance teams involved in the preparation and release of the WCB for GMP manufacturing operations.

3. Responsibilities

  • CLD Scientist: Expands MCB vial, prepares WCB batches under aseptic conditions, and oversees cryopreservation.
  • QC Analyst: Performs viability, sterility, mycoplasma, and identity testing on WCB vials.
  • QA Officer: Reviews batch records and approves WCB release for manufacturing use.
See also  Biosimilars: SOP for Western Blotting for Protein Expression - V 2.0

4. Accountability

The Head of CLD is accountable for ensuring the WCB is traceable, well-characterized, and GMP-compliant, with all activities documented and archived.

5. Procedure

5.1 MCB Revival and Expansion

  1. Thaw a vial from the released MCB under aseptic conditions in a biosafety cabinet.
  2. Expand cells in T-flasks and spinner flasks over 2–3 passages using production media.
  3. Monitor cell density, morphology, and viability at each passage.

5.2 Harvest and Viability Check

  1. Harvest cells when viable cell density reaches 2–5 × 106 cells/mL with ≥95% viability.
  2. Centrifuge at 300 × g for 5 minutes and resuspend in pre-chilled cryopreservation media (90% production medium + 10% DMSO).

5.3 Aliquoting and Labeling of WCB Vials

  1. Dispense 1.0 mL per vial (target ≥ 100 vials) into sterile, labeled cryovials.
  2. Label to include:
    • Cell Line ID
    • WCB Lot No.
    • Date of Freezing
    • Passage No.
    • Technician Initials
See also  Biosimilars: SOP for Gene Copy Number Determination - V 2.0

5.4 Controlled Rate Freezing

  1. Freeze vials in a controlled-rate freezer at -1°C/min to -80°C.
  2. Transfer to liquid nitrogen storage after 12–18 hours.

5.5 QC Testing of WCB

  1. Send representative vials for:
    • Cell viability (Trypan Blue)
    • Sterility (USP <71>)
    • Mycoplasma testing (PCR and culture)
    • Identity confirmation (STR profiling)
  2. Record results in WCB QC Log (Annexure-1).

5.6 Documentation and Release

  1. Complete batch records for freezing, QC results, and inventory.
  2. Prepare Certificate of Analysis and submit for QA review.
  3. Release WCB after QA approval with full documentation.

6. Abbreviations

  • WCB: Working Cell Bank
  • MCB: Master Cell Bank
  • DMSO: Dimethyl Sulfoxide
  • STR: Short Tandem Repeat

7. Documents

  1. WCB QC Log (Annexure-1)
  2. WCB Freezing and Labeling Record (Annexure-2)

8. References

  • ICH Q5D – Cell Substrate Derivation and Characterization
  • WHO TRS 978 – GMP for Cell Banks
  • CDSCO Biosimilar Quality Guidelines (India)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: WCB QC Log

Test Method Result Acceptance Criteria Status
Viability Trypan Blue 96% ≥ 85% Pass
Sterility USP <71> Negative No Growth Pass
Mycoplasma PCR Negative Absent Pass
STR Profile Capillary Electrophoresis Matched 100% Match Pass

Annexure-2: WCB Freezing and Labeling Record

Vial No. WCB Lot No. Cell Line ID Freezing Date Location Operator
WCB001 WCB-BS-25A CL-BS-025 03/05/2025 T2/R3/B5 Rajesh Kumar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated QC panel and added C of A preparation Audit Recommendation
See also  Biosimilars: SOP for Selection of Stably Transfected Clones - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for Crossover Period Washout Management – V 2.0
Next Post: Aerosol: SOP for Periodic Review of Cleaning Validation Data – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version